RET and medullary thyroid gland carcinoma: Lastly, in peculiar setting of pediatric patients, selpercatinib was useful to control the disease, in absence of relevant TEAEs, in 2 patients with RET-mutant MTC who experienced loss of clinical benefit with previous MKIs treatment (143).